title: Short-term outcome of infants presenting to pediatric intensive care unit with new cardiac diagnoses.
abstract: OBJECTIVE
  To outline the etiology, clinical course, short-term survival to discharge and neurological outcome of infants (<1 yr) with new cardiac diagnoses presenting to a pediatric intensive care (PICU) unit with acute cardiac compromise.
  
  
  METHODS
  Retrospective search of a computerized database and medical case notes for all acute cardiac admissions to PICU from June 2001 to 2006. Pre-existing hospital-based patients with new cardiac diagnoses were excluded.
  
  
  RESULTS
  Seventy patients were identified, 38 (54%) of whom were male. There were six main subgroups: obstructive left heart lesions (n= 20), transposition of the great arteries (TGA) (n= 9), total anomalous pulmonary venous drainage (TAPVD) (n= 7), dilated cardiomyopathy (n= 11), arrhythmia (n= 12), and others (n= 11). Fifty-nine patients (84%) were external referrals to our center. The median age at presentation was 13.5 days (0-272) with median duration of symptoms of 1 day (0-21). The median base deficit at presentation was -7.6 mEq/L (-43 to +4.2). Fifty-three patients (76%) required respiratory support with a median duration of ventilation of 4 days (1-49). Fifty-six patients (80%) required inotropic support. The median PICU stay was 7 days (1-64) with a median total hospital stay of 16 days (1-71). Six patients (9%) died prior to discharge. Of the survivors 7 (11%) had seizure activity or evolving clinical neurological abnormalities.
  
  
  CONCLUSIONS
  Cardiovascular compromise due to previously unrecognized congenital or acquired heart disease is associated with clinically significant morbidity and mortality. Longer term follow-up is required to evaluate the initial effect of poor cardiac output and hypoxia on long-term neurodevelopmental outcome.
authors.affiliation: Bristol Royal Hospital for Children-Bristol Congenital Heart Centre, Bristol, UK. damienkenny@doctors.org.uk
authors.forename: Giridhar
authors.initials: G
authors.lastname: Dhandayuthapani
authors.forename: Shanta
authors.initials: S
authors.lastname: Chakrabarti
authors.forename: Aruna
authors.initials: A
authors.lastname: Ranasinghe
authors.forename: Linda
authors.initials: L
authors.lastname: Hunt
authors.forename: David
authors.initials: D
authors.lastname: Grant
authors.forename: Robin P
authors.initials: RP
authors.lastname: Martin
authors.forename: Damien
authors.initials: D
authors.lastname: Kenny
mesh_terms: D002316:Cardiotonic Agents / Q000627:therapeutic use; D002657:Child Development; D057210:Delayed Diagnosis; D004739:England; D005260:Female; D006331:Heart Diseases / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D017052:Hospital Mortality; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015278:Intensive Care Units, Pediatric / Q000706:statistics & numerical data; D007902:Length of Stay; D008297:Male; D009420:Nervous System / Q000254:growth & development; D010043:Outcome and Process Assessment, Health Care / Q000706:statistics & numerical data; D010351:Patient Discharge; D012121:Respiration, Artificial; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012640:Seizures / Q000209:etiology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents